Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $16000.0.

  • BioXcel Therapeutics' Gains from Investment Securities changed N/A to $16000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $68000.0, marking a year-over-year decrease of 7004.41%. This contributed to the annual value of $59000.0 for FY2024, which is 7677.17% down from last year.
  • Latest data reveals that BioXcel Therapeutics reported Gains from Investment Securities of $16000.0 as of Q3 2025.
  • BioXcel Therapeutics' Gains from Investment Securities' 5-year high stood at $4.8 million during Q1 2024, with a 5-year trough of -$343000.0 in Q4 2022.
  • Its 4-year average for Gains from Investment Securities is $563444.4, with a median of $51000.0 in 2024.
  • As far as peak fluctuations go, BioXcel Therapeutics' Gains from Investment Securities soared by 1785555.56% in 2024, and later crashed by 9997.94% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Gains from Investment Securities stood at -$343000.0 in 2022, then surged by 166.18% to $227000.0 in 2023, then crashed by 77.53% to $51000.0 in 2024, then plummeted by 68.63% to $16000.0 in 2025.
  • Its Gains from Investment Securities stands at $16000.0 for Q3 2025, versus $1000.0 for Q1 2025 and $51000.0 for Q4 2024.